What Does It Mean to Get Diagnosed with Lynch Syndrome?
Three patients share their experiences about having Lynch syndrome.
Progress Against Cancer
Three patients share their experiences about having Lynch syndrome.
Improvements in medical care have reduced the rate of relapse in acute myeloid leukemia after transplants, helped people live longer, and reduced mortality from other causes, according to large set of data. Older patients...
Researchers are exploring new options for kidney cancer treatments.
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for adult patients...
Modified CAR T-cell therapy shows promise in glioblastoma, and an immunotherapy may soon be available as an injection.
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory...
Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who...
Why do many Asian American women who have never smoked have lung cancer, and a report finds acne products can create cancer-causing benzine.
A new treatment regimen that includes a Bruton’s tyrosine kinase inhibitor was approved for follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanubrutinib (Brukinsa) in combination with obinutuzumab...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More